CA-IMPERVA
3.11.2022 13:02:06 CET | Business Wire | Press release
Imperva, Inc., (@Imperva) the cybersecurity leader whose mission is to help organizations protect their data and all paths to it, releases The State of Security Within eCommerce 2022 report, a 12-month analysis by Imperva Threat Research of cybersecurity threats targeting the retail industry. A range of automated threats -- from account takeover, credit card fraud, web scraping, API abuses, Grinch bots, and distributed denial of service (DDoS) attacks -- were a persistent challenge for the eCommerce industry, threatening online sales and customer satisfaction. The continued barrage of attacks on retailers’ websites, applications, and APIs throughout the calendar year, and during the peak holiday shopping season, is a continued business risk for the retail industry.
“The holiday shopping season is a critical period for the retail industry, and security threats could undermine retailers’ bottom line again in 2022,” says Lynn Marks, Senior Product Manager, Imperva. “This industry faces a variety of security risks, the majority of which are automated and operate around the clock. Retailers need a unified approach to stop these persistent attacks, one that focuses on the protection of data and is equipped to mitigate attacks quickly without disrupting shoppers.”
An Automated Adversary: Bad Bots & Online Fraud Plague Retail Sites
In the past 12 months, nearly 40% of traffic on retailers’ websites didn’t come from a human. Instead, it came from a bot, software applications controlled by operators that run automated tasks, often with malicious intent. In the retail industry, the infamous Grinch bot is notorious for inventory hoarding during the holiday shopping season, scooping up high-demand items and making it challenging for consumers to purchase gifts online.
Some of the key trends monitored by Imperva include:
- Of all the traffic on retailers’ websites, nearly one-quarter (23.7%) was attributed specifically to bad bots, malicious automation that contributes to online fraud. The proportion of advanced bots -- scripts that use the latest evasion techniques to mimic human behavior and avoid detection -- on retail sites grew over the prior year (from 23.4% to 31.1%). Advanced bots are a considerable challenge for organizations to stop without the right defenses in place.
- In 2021, bot-related attacks on retail sites grew 10% in October and grew another 34% in November, suggesting that bot operators increase their nefarious efforts around peak holiday shopping periods.
- Account takeover (ATO) is another form of online fraud in which cybercriminals attempt to compromise online accounts by using stolen passwords and usernames. In 2021, 64.1% of ATO attacks used an advanced bad bot. Of all login attempts on retail websites, 22.6% were malicious, nearly twice the volume that was recorded on sites across other industries. Attackers used leaked credentials 94.7% of the time in credential stuffing attacks targeting retailers, compared to 69.6% of the time in other industries.
API Abuses and Attacks Multiply, Creating New Challenges for Retailers
APIs are the invisible connective tissue that enable applications to share data and invoke digital services. Analysis by Imperva Threat Research finds that traffic from an API accounts for 41.6% of all traffic to online retailers’ sites and applications. Of that, 12% of traffic directs to endpoints, like a database, where personal data is stored (e.g. credentials, identification numbers, etc.). More concerning, 3 - 5% of API traffic is directed to undocumented or Shadow APIs, endpoints that security teams don’t know exist or no longer protect.
Exposed or vulnerable APIs are a considerable threat for retailers because attackers can use the API as a pathway for exfiltrating customer data and payment information. API abuses are often carried out through automated attacks where a botnet floods the API with unwanted traffic, seeking vulnerable applications and unprotected data. In 2021, API attacks increased by 35% between September and October, and then spiked another 22% in November on top of the previous months’ elevated attack levels. This finding suggests that bad actors scale their efforts around the holiday shopping season as more data is exchanged between the APIs and applications that power eCommerce services.
Beware of Downtime: DDoS Attacks Continue to Threaten Retailers
A distributed denial of service (DDoS) attack is an automated threat that attempts to disrupt critical business operations by flooding the network or application infrastructure with malicious traffic. The attacks are often launched by a botnet, a group of compromised connected devices that are distributed across the Internet and operated by a single party.
Imperva Threat Research finds that DDoS attacks in 2022 are larger and stronger across all industries. The number of incidents recorded that were greater than 100 Gbps doubled, and attacks larger than 500 Gbps/0.5 Tbps increased 287%. What’s more, those targeted by an attack are often attacked again within 24 hours. In fact, 55% of websites hit by an application layer DDoS and 80% hit by a network layer DDoS were attacked multiple times.
A DDoS attack is a nonstop threat for retailers. The downtime caused by a DDoS attack can lead to site disruption, reputational damage, and revenue loss. A DDoS is a critical threat to online retailers that rely on application performance and availability to enable digital storefronts.
Additional Information:
- Download the The State of Security Within e-Commerce 2022 report
- Learn how Imperva products and solutions help retailers protect their applications, APIs, and data from security risks.
- See how bad bots create business disruption across different industries.
- Check out the Imperva Blog for the latest product and solution news, and threat intelligence from Imperva Threat Research.
About Imperva:
Imperva is the comprehensive digital security leader on a mission to help organizations protect their data and all paths to it. Only Imperva protects all digital experiences, from business logic to APIs, microservices, and the data layer, and from vulnerable, legacy environments to cloud-first organizations. Customers around the world trust Imperva to protect their applications, data, and websites from cyber attacks. With an integrated approach combining edge, application security, and data security, Imperva protects companies ranging from cloud-native start-ups to global multi-nationals with hybrid infrastructure. Imperva Threat Research and our global intelligence community keep Imperva ahead of the threat landscape and seamlessly integrate the latest security, privacy, and compliance expertise into our solutions.
© 2022 Imperva, Inc. All rights reserved. Imperva is a registered trademark of Imperva, Inc.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221103005435/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
